Navigation Links
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Date:1/8/2008

rate, the Company has proposed an amended trial to continue its interest in the relapsed setting.

An agreement has been reached with the FDA on modifications to Vion Study CLI-037. The revised study includes a lower dose of Cloretazine(R) (VNP40101M) in the experimental arm of the trial and prophylactic therapy with antibiotics, antifungals and growth factors for all patients. In order to maintain the Special Protocol Assessment (SPA) with the FDA for this trial, the next step is to submit an SPA to the FDA with these modifications before recommencing the trial.

Dr. Frank Giles, Chief of the Division of Hematology and Medical Oncology at the University of Texas Health Science Center at San Antonio, and lead investigator on the Cloretazine(R) clinical program stated, "Cloretazine(R) has recently shown very significant single agent activity in a the difficult to treat elderly AML patient population. It is important that we now establish the optimal dosing schedule in combination with other chemotherapeutic agents, such as cytarabine." He concluded, "Modifications to this Phase III trial in patients with relapsed AML will allow us to examine a combination schedule that should maintain the activity observed in the initial portion of the study with an acceptable marrow toxicity profile."

The Company also announced plans to file an abstract on data from Vion Study CLI-037 for the Annual Meeting of the American Society of Clinical Oncology (ASCO(R)) in June 2008.

Ann Cahill, Vice President, Clinical Development, commented, "Cloretazine(R) (VNP40101M) is an active agent in AML, and we continue to believe that it will have clinical utility in both the frontline and second line settings, as either a single agent or in combination with other therapies."

The Company has announced previously that it plans to file a New Drug Application with the FDA in 2008 based on a pivotal Phase II study of Cloretazine(R) (VNP40101M) as a single agent in eld
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)...   Heska Corporation (NASDAQ: HSKA - ... advanced veterinary diagnostic and other specialty veterinary products , ... present at the 16th Annual B. Riley & Co. Investor ... conference will be held May 12-14, 2015 at Lowes Hollywood ... will be available during the day on May 13 for ...
(Date:5/1/2015)... May 1, 2015 At the American Association ... Washington D.C. , Elekta will highlight ... enables clinicians to leverage the enormous amount of data ... conducted each year – to advance clinical research and ... is a cloud-based solution that allows practitioners to store, ...
(Date:5/1/2015)... May 1, 2015 Braeburn Pharmaceuticals ... current therapeutic focus beyond addiction and pain ... disorders. Braeburn has acquired an implantable, six-month ... risperidone for treatment of schizophrenia from Endo ... global rights to other potential applications of ...
Breaking Medicine Technology:Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4
... SILVER SPRING, Md., Sept. 14, 2011 The U.S. ... companies have agreed to halt distribution of amino-acid products ... of the Federal Food, Drug, and Cosmetic Act are ... West Duluth Distribution Co., a corporation doing business as ...
... Ga., Sept. 14, 2011 Greenway Medical Technologies, ... Inland Northwest Health Services (INHS) today announced an ... health record (EHR) and practice management solution ... practices requiring advanced care coordination and network interoperability. ...
Cached Medicine Technology:FDA: Minnesota Companies Agree to Halt Sale of Amino-acid Products with Unapproved Claims 2FDA: Minnesota Companies Agree to Halt Sale of Amino-acid Products with Unapproved Claims 3Greenway Partners With INHS to Advance EHR Adoption 2Greenway Partners With INHS to Advance EHR Adoption 3
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part of ... technology products available to consumers. Scott Steinberg, a technology expert ... with viewers how to protect their private information. , A ... and even more so online. It helps everyone stay connected ... world. In terms of work, the internet makes things more ...
(Date:5/3/2015)... MA (PRWEB) May 03, 2015 SpineFrontier, ... clearance from the FDA to produce and market their ... device can be used in outpatient settings and is ... The alternate posterior approach has been extensively researched and ... 510k approval to use this approach in conjunction with ...
(Date:5/2/2015)... As one of only 30 Illinois companies to be ... and Recognition Program (SHARP) certification, Essentra Specialty Tapes ... Department of Labor to host this special event. ... the Occupational Safety and Health Administration’s (“OSHA”) Onsite Consultation ... or exceed all of the necessary regulations and standards, ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 “ ActOn ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... to get connected with organizations to make a difference. , ... are very few things that aren’t about money, which is ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2
... say , MONDAY, Oct. 29 (HealthDay News) High-dose ... prostate cancer patients, U.S. researchers say. , A team ... men with intermediate- to high-risk prostate cancer who underwent ... targets the tumor. , "IMRT is revolutionizing how we ...
... (brachytherapy) are just as effective at curing prostate cancer ... are in older men, according to a study presented ... the American Society for Therapeutic Radiology and Oncologys 49th ... minimally invasive procedure where a radiation oncologist places small ...
... type of drug called a pharmaceutical monoclonal antibody to ... effect of radiation therapy for lung cancer patients ... lives and improving their quality of life, according to ... October 29, 2007, at the American Society for Therapeutic ...
... of the National Institutes of Health, has awarded Rhode ... prevention and treatment of skeletal joint diseases. The 5-year ... (COBRE) for Skeletal Health and Repair at Rhode Island ... its academic partner, The Warren Alpert Medical School of ...
... will appear in conjunction with Kellogg Insight research,digest ... Kellogg School,of Management at Northwestern University today announced ... by David Dranove, the Kellogg School,s,Walter J. McNerney ... accessible at the following link:, http://insight.kellogg.northwestern.edu/index.php/codered ., ...
... global health and socio-economic factors ... YORK, Oct. 29 The 20th century ushered ... health. However, the,increased incidence and burden of major ... of tuberculosis, present critical,health challenges to the global ...
Cached Medicine News:Health News:Prostate Cancer Radiotherapy Won't Affect Sexual Function 2Health News:Radiation seeds effectively cure prostate cancer in young men 2Health News:Preventing lung scarring may extend lives of lung cancer patients 2Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 2Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 3Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 4Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 5Health News:Kellogg School of Management Announces 'Code Red' 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 3Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 4
... Biomet® Retrograde Femoral Nail ... the advantages of optimal ... straight nail designs. Furthermore, ... promote ease-of-use with desired ...
... latest in the Magnes line of biomagnetometer systems, ... full cortical coverage, provides the highest detector density ... of a wide range of neuronal activity. The ... detector configurations and can be equipped with radial ...
... Four-channel neurodiagnostic for basic ... EP. Incorporates a large 12.1" ... Advanced engineering and the latest ... performance and speed, advanced NCS ...
... stimulation is a non-invasive and painless method ... system. Cadwell Laboratories manufactures two magnetic stimulation ... Magnetic Stimulator (HSMS). The Hight Speed MES-10 ... up to 25 Hz at full power. ...
Medicine Products: